We would like to thank the following organisations for supporting the 2019 Gala Dinner.
With more than 35 years representing life sciences clients, Cooley has been at the forefront working alongside leading life sciences companies across the globe. Our clients include both high-growth and mature companies as well as entrepreneurs, venture capitalists and financial institutions. We represent more than 1,200 life sciences companies and medical technologies companies worldwide.
Cooley has been involved with hundreds of transactions across various technologies and stages of product development and are widely recognized as best-in-class in handling corporate partnering and licensing transactions. We have handled more than 1,000 M&A transactions since 2010 and understand unique structuring issues for life sciences companies, including milestone structures, contingent value rights and option structures. We are the #1 ranking firm in the representation of U.S. issuer-side life science IPOs since 2000 per IPO Vital Signs. Our team includes leading regulatory lawyers and over 70 life sciences patent lawyers and professionals.
Oxford BioMedica (OXB) is a leading gene and cell therapy group focused on developing life changing treatments for serious diseases. OXB has built a sector leading lentiviral vector delivery platform (LentiVector®) to develop in vivo and ex vivo products both in-house and with partners. OXB has entered into a number of partnerships, including with Novartis, Bioverativ, Sanofi, Axovant and others. OXB has world class facilities and capabilities to support pre-clinical, research and bioprocessing development through to GMP production and supply of commercial and clinical trial materials. Oxford BioMedica is based across several locations in Oxfordshire, UK and employs more than 360 people.